A faster return to growth for AstraZeneca?
This article was originally published in Scrip
Executive Summary
Pascal Soriot, AstraZeneca's CEO, took his podium opportunity at the JP Morgan conference to have a quick swipe at GlaxoSmithKline over its problems in China, while trying to persuade the audience that AstraZeneca "can return to growth faster that most people have been forecasting."